- Datum30.06.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Altan Cantürk
Moderator
Leap Therapeutics Inc. Aktie
Verkaufen
Kaufen
Leap Therapeutics Inc. Chart
Echtzeit-News zu diesem und anderen Unternehmen findest Du hier!
Live-Ticker Leap Therapeutics Inc. Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| L&S | VK | |||||
| Tradegate | VK | |||||
| Stuttgart | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
-0,07 %
Intraday
-25,86 %
1 Woche
-26,64 %
1 Monat
-90,28 %
Seit Jahresbeginn
-84,21 %
1 Jahr
-97,88 %
3 Jahre
-98,71 %
5 Jahre
Passender Service zu Leap Therapeutics Inc.
Webinar zu Leap Therapeutics Inc.
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)0,222-4,790
- Jahrestief / Hoch ($)0,222-3,580
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Leap Therapeutics Inc.
Keine Dividenden verfügbar
Termine von Leap Therapeutics Inc.
Keine aktuellen Termine
Beschreibung
Leap Therapeutics Inc is a biopharmaceutical company developing novel therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways and by harnessing the immune system to attack cancer cells. Its clinical stage program is DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, or DKK1. DKK1 is a protein that regulates the Wnt signaling pathways and enables tumor cells to proliferate and spread, as well as suppresses the immune system from attacking the tumor. The company is studying DKN-01 in multiple ongoing clinical trials in patients with esophagogastric cancer, gynecologic cancers, or prostate cancer. Its other clinical studies include P204,and P205.
